Jazz Pharmaceuticals JAZZ Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $293.1M+417% | —— | $251.41M+16.9% | -$718.47M-526% | -$92.5M-533% | ||
| $9.1M-12.5% | $9.43M-0.9% | $9.88M+27.0% | $11.93M+52.7% | $10.4M+35.9% | ||
| $74.5M+10.0% | $70.85M+0.9% | $88.13M+47.5% | $64.45M+13.8% | $67.7M+10.2% | ||
| -$66.2M-51.1% | -$63.31M-2,588% | -$271.41M-321% | -$66.45M+11.6% | -$43.8M+34.0% | ||
| $122.8M— | —— | —— | —— | $0— | ||
| $6.5M+110% | $65.81M— | $51M+129% | $55.47M+736% | -$66M-882% | ||
| $77.8M+119% | $0-100% | $31.91M+244% | $26.25M+453% | $35.6M+177% | ||
| -$21.4M-212% | —— | $62.36M+588% | —— | $19.1M+197% | ||
| -$7.9M-104% | $26.17M-12.0% | $126.28M+147% | -$256.35M— | $181M+422% | ||
| -$51.9M-7,002% | -$11.01M-127% | -$18.82M-590% | $50K-96.9% | $752K-81.6% | ||
| $12.2M+321% | $22.73M+157% | $529K-75.5% | $1.86M— | $2.9M+176% | ||
| -$3.9M-160% | —— | -$1.02M+75.2% | -$13.54M-1,501% | $6.5M+144% | ||
| $37.4M+188% | —— | $12.74M+516% | $46.27M+1,359% | $13M-12.5% | ||
| $172.3M+11.6% | $169.74M+6.8% | $168.37M+6.9% | $162.1M+4.4% | $154.4M-0.9% | ||
| $408.2M-5.0% | $362.52M-9.0% | $474.62M+19.0% | $88.84M-73.2% | $429.8M+60.8% | ||
| $19.7M+41.7% | $16.73M+25.9% | $15.18M+40.7% | $12.95M+82.6% | $13.9M+101% | ||
| $500M+13.6% | $510.1M+8.5% | $640.13M+392% | $239.95M-27.3% | $440.1M+17.4% | ||
| $520M+67.7% | $180M-37.9% | $400M+12.7% | $470M+488% | $310M+158% | ||
| $200M— | —— | —— | —— | $0— | ||
| $0-100% | $53.5M— | $30M— | $0— | $25M— | ||
| $123.1M+173% | -$372.16M-92.5% | -$327.8M— | -$640.95M-149% | -$169M+37.8% | ||
| $32.9M+186% | $85.19M+826% | $733K+4,212% | $10.44M-4.5% | $11.5M+2,228% | ||
| $103.6M+54.2% | $2M-50.2% | $3.81M+138% | $2.21M-22.3% | $67.2M+36.3% | ||
| -$78.5M+90.4% | $0— | -$10.83M-104% | -$124.49M+22.7% | -$813.5M-1,338% | ||
| -$400K-124% | $33K+101% | $203K-93.4% | $4.62M+709% | $1.7M+200% | ||
| $452.4M+182% | —— | —— | -$671.98M-667% | -$551M-776% | ||
| —— | $62.14M-21.0% | $62.14M-21.0% | $62.14M-21.0% | $62.14M-21.0% | ||
| —— | $30.45M+6.0% | $30.45M+6.0% | $30.45M+6.0% | $30.45M+6.0% | ||
| $172.3M+11.6% | $169.74M+6.8% | $168.37M+6.9% | $162.1M+4.4% | $154.4M-0.9% | ||
| $9.1M-12.5% | $9.43M-0.9% | $9.88M+27.0% | $11.93M+52.7% | $10.4M+35.9% | ||
| $122.8M— | —— | —— | —— | $0— | ||
| -$51.9M-25.4% | -$27.49M-220% | —— | —— | -$41.4M+24.7% | ||
| $37.5M+25.4% | $40.6M+7.4% | $40.36M+15.2% | $37.09M+11.6% | $29.9M+3.3% | ||
| $4.7M-72.5% | $5.33M+72.1% | $5.3M-31.0% | $4.81M-7.6% | $17.1M+186% | ||
| -$3.9M-160% | —— | -$1.02M+75.2% | -$13.54M-1,501% | $6.5M+144% | ||
| $14.2M+168% | $4.11M-65.4% | $8.22M+207% | $1.47M-74.6% | $5.3M-28.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $0-100% | $53.5M— | $30M— | $0— | $25M— | ||
| $77.2M— | —— | —— | —— | $0— | ||
| $520M+67.7% | $180M-37.9% | $400M+12.7% | $470M+488% | $310M+158% | ||
| $200M— | —— | —— | —— | $0— | ||
| $32.9M+186% | $85.19M+826% | $733K+4,212% | $10.44M-4.5% | $11.5M+2,228% | ||
| $7.8M-99.0% | $7.75M0.0% | $7.75M0.0% | $7.7M-0.6% | $757.8M+9,678% | ||
| —— | $30.45M+6.0% | $30.45M+6.0% | $30.45M+6.0% | $30.45M+6.0% | ||
| $388.5M-6.6% | $345.79M-10.3% | $459.44M+18.4% | $75.89M-76.6% | $415.9M+59.8% | ||
| $388.5M-6.6% | $345.79M-10.3% | $459.44M+18.4% | $75.89M-76.6% | $415.9M+59.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Jazz Pharmaceuticals generate?
- Jazz Pharmaceuticals (JAZZ) generated $1.3B in operating cash flow over the trailing twelve months.
- What is Jazz Pharmaceuticals's free cash flow?
- After $64.6M of capital expenditures, Jazz Pharmaceuticals's free cash flow was $1.3B over the trailing twelve months, down 16.1% year over year.
- Where does Jazz Pharmaceuticals's cash flow data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
